Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 521–530 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 521
- Medicine slug
- emtricitabine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
1–2 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d6599395-3944-44f9-97f2-e0424c6b6a1f (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
Figure 1 Mean (± 95% CI) Steady-State Plasma FTC Concentrations in HIV-1 Infected Adults (N=20) Figure 1 Absorption Emtricitabine is rapidly and extensively absorbed following oral administration, with peak plasma concentrations occurring at 1–2 hours postdose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cdfb7868-3eba-46e1-a286-ca40760fd98d (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
Figure 1 Mean ( ± 95% CI) Steady-State Plasma FTC Concentrations in HIV‑1 Infected Adults (N=20) Absorption Emtricitabine is rapidly and extensively absorbed following oral administration, with peak plasma concentrations occurring at 1 to 2 hours postdose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a229c922-58eb-4795-9219-6cebb1779e35 (opens source in a new tab)
Emtricitabine label
Version not recorded · Effective date not recorded
Figure 1 Mean (± 95% CI) Steady-State Plasma FTC Concentrations in HIV-1-Infected Adults (N=20) Absorption Emtricitabine is rapidly and extensively absorbed following oral administration, with peak plasma concentrations occurring at 1-2 hours postdose.
Projected row 522
- Medicine slug
- enalapril
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 69
- Source count
- 66
- Agreement rate
- 1
- Recorded readings
14 hours
- Numeric value
- 14
- Unit
- hours
- Source records
- 66
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 66 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9391b8d8-2217-4838-8976-1a5ad90ef4ca (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7b80abb4-fa75-48a4-a2e9-b0e31205234c (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68 percent of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0ad4bfb4-62db-4759-af60-88eb031d125a (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e81a8aca-0e7c-4a02-b596-09e4ac22c70e (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady-state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b1df1832-dce4-443f-87fc-e4177d069035 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7934b45-eb6b-44c1-bd2c-ef0fa10850c1 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6dbda02-779e-420c-893d-d0fea09432be (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e277302-6e6c-4a95-8f25-aaff64fb0b82 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39631f1f-5d19-43c1-b504-bf56d991ed97 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ebd2a62d-a704-4f8a-a104-749a5296502f (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fd013f06-3456-c178-e053-6294a90a6bd9 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0b3dbe11-ff75-cb98-e063-6294a90ad2e9 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a5c6e64c-a3ed-44f2-83e7-f4b62b6cd622 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab2ffb6e-4628-e44c-e053-2a95a90a2336 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29ef93b-7380-2196-e053-2995a90a2ce3 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1e4cd79-ece5-432c-bd3a-ed4633ccec70 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:964d561a-2e04-4ad9-9762-932419ee19ae (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0c829189-fba2-48f8-a23f-d5471a0345f6 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fa93d8e6-2ed2-4a3c-bf6d-33bd0a374efa (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:508a58fa-9f66-e984-e063-6394a90a296a (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:337707cc-4ed9-4121-bfff-c5015e5eca9d (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2e4ecc3a-ec6d-418b-99a8-95ad3e1c59d6 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb3c7066-76cb-4e8e-b98b-bcb41a3631df (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0a12343f-5733-40cc-93b4-a02f5147fb91 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:074fe718-88d8-365c-e063-6394a90a299d (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e47afc0d-afc4-4972-a28a-5d3c640390ab (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed7536f1-9a7d-4519-e053-2a95a90a4a65 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5118eb9f-1466-4318-b17e-cf5898edbeef (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b63bdaa6-b57b-417b-9a79-29f1fd5bbf08 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3754f29-9b75-4e2c-9c28-b3479f5bf906 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec6c8c65-b438-40e3-9eb3-665d939abbdb (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a8ca159-c4c7-468a-bcc2-d1b879ea2c7e (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2b3776b-02a1-311b-e053-2a95a90a2f9b (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dfc439f7-83f5-4b9e-bbf2-f3d002860be3 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe2dfa84-0276-6603-e053-6394a90af8ee (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc892e2-1d91-e52a-e063-6394a90a6649 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2061543d-67e7-46b6-aa56-cafa11ae4b93 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ccdd0f67-e9d5-41e3-93d5-94b9792a6f8f (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e109e7b1-4650-4416-9d89-7c1185d5cf48 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68 percent of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ed266486-e4a5-9dd1-e053-2a95a90a80d3 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f103b9f9-e081-419d-a2d8-b86acda834dd (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a88902bd-742f-4ea6-b625-cc9df1709efc (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4b7b936-4a62-4991-8d3c-03bb37f044c1 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:898b36d6-320f-4d6c-9734-0be8363dc3d7 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:71e9fff3-7283-437e-b107-72fc16f09989 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5596ba00-4a1c-4503-99db-3a9617ed17c0 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdb34c96-1532-4ce5-93a7-3cc90904c910 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:19606da3-c6b0-40a5-9690-77fc37072b51 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe303f6a-4a9f-259e-e053-6394a90af16b (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bc875f91-d781-43a9-8f7e-e2cfc019ad3f (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f913e79-fe6d-4ff2-9f8e-eef9df689fa8 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eee8633b-9d9e-453d-8c6b-8b13c94d2f58 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fdc2d8a-9b5d-43c4-b32f-6f2505aee33c (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ca1d0143-bbd3-4041-9981-eadbb8893a2b (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cbaaa849-0f9d-4294-b122-090ff17fdcc7 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3fbc6cce-7ad5-49d5-9705-5f66ef92d544 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f2a0bd73-0389-3f88-e053-2995a90a72e8 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c49fb37-1f09-4965-b213-5580d3a30a11 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:315baaa6-512c-f27b-e063-6294a90a2c91 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b31372f7-cda3-4ead-a481-4cde62e843fd (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59f44ba0-a323-493f-e063-6394a90a1c3c (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7077d32e-4b06-4d48-ba0c-6db2f8ebe08c (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:cc921315-8da1-487c-ba19-433470f5c8d8 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4f56955c-fc61-49ad-b42f-ff9d3386af6a (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8fe8dc52-dee6-4d33-b798-e90128011f46 (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1b464099-491d-473b-836e-9d86b2b1eeec (opens source in a new tab)
Enalapril label
Version not recorded · Effective date not recorded
At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours, and the mean urinary recovery of total enalapril and enalaprilat in 24 hours was 68% of the administered dose.
Projected row 523
- Medicine slug
- enoxaparin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
4.5 hours
- Numeric value
- 4.5
- Unit
- hours
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa78f8d-92d9-434a-8e26-b886ab0ae77f (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de6fb917-a94a-41ea-9d7d-937d4080ffcd (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e7568a6-cf8a-4de2-86ba-b94c8ab4c806 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3be543e-8aff-4311-bf77-e7a5a814ca6f (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31e7c4d0-ba45-4b20-8e25-2d12892372e5 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21b095d1-5ade-43e9-9114-30fbfb2331c9 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f60bd8-b518-4098-a808-b8f5a3ae6a3a (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5017a927-2a24-4f27-89f9-27c805bf7d59 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4728749-8453-4f07-9fbc-a1f3e9d2708b (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32f8d292-0dda-4931-81ea-ba47e23edf61 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2a8615b-a27e-4ab2-ae4c-592bbf4643c0 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e2875df-0f0c-46ec-990f-69108f383f58 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:066f27ec-352c-4051-ba29-248e292690db (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8afb29f-cbed-43bc-809f-09b30fca28f5 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d978e06e-b758-460b-81d3-69f7a5b89b00 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:014c6710-f2c4-fd1e-e063-6394a90ae525 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d263380-4f44-4fd8-aa2a-e69702ab258f (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adbba7bb-fa72-4cec-aa69-13965591a45d (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fb85ab-1fe5-4dd3-a97f-adbed0674f67 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e6bf2b3-9339-4104-bda3-ad86a1949703 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65025e0d-eb54-4c4e-bd14-f294ce038902 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a66675-b159-42b8-9f18-ff80f28e1503 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20635579-c92d-4f6c-a332-1096d51002f2 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adfc2b23-00a5-4f05-a08b-83087e1e4843 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419a3566-4f67-4c8d-86e5-c00c7ec429e1 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d38c307-767f-4c38-ac0e-b8bb62782602 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7197534-1daa-42de-8b83-a727da1195bf (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a694bbc3-4eb0-4c1e-b4ff-b8abc3e5148e (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single subcutaneous dose to about 7 hours after repeated dosing.
Projected row 524
- Medicine slug
- enoxaparin
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 28
- Source count
- 28
- Agreement rate
- 1
- Recorded readings
4.3 L
- Numeric value
- 4.3
- Unit
- L
- Source records
- 28
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 28 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7fa78f8d-92d9-434a-8e26-b886ab0ae77f (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% * Means ±SD at Day 5 and 90% Confidence Interval (CI) of the ratio † Median (range) Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de6fb917-a94a-41ea-9d7d-937d4080ffcd (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e7568a6-cf8a-4de2-86ba-b94c8ab4c806 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
s) (h IU/mL or h * Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3be543e-8aff-4311-bf77-e7a5a814ca6f (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h*IU/mL or h * Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105–112% 103–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31e7c4d0-ba45-4b20-8e25-2d12892372e5 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:21b095d1-5ade-43e9-9114-30fbfb2331c9 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h IU/mL or h Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:38f60bd8-b518-4098-a808-b8f5a3ae6a3a (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
s) (h IU/mL or h * Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5017a927-2a24-4f27-89f9-27c805bf7d59 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4728749-8453-4f07-9fbc-a1f3e9d2708b (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105–112% 103–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32f8d292-0dda-4931-81ea-ba47e23edf61 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105% to 112% 103% to 109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a2a8615b-a27e-4ab2-ae4c-592bbf4643c0 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105% to 112% 103% to 109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9e2875df-0f0c-46ec-990f-69108f383f58 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
e ratio IU/mL or h † sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:066f27ec-352c-4051-ba29-248e292690db (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d8afb29f-cbed-43bc-809f-09b30fca28f5 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105% to 112% 103% to 109% * Means ±SD at Day 5 and 90% Confidence Interval (CI) of the ratio † Median (range) Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d978e06e-b758-460b-81d3-69f7a5b89b00 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:014c6710-f2c4-fd1e-e063-6394a90ae525 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d263380-4f44-4fd8-aa2a-e69702ab258f (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adbba7bb-fa72-4cec-aa69-13965591a45d (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105% to 112% 103% to 109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b6fb85ab-1fe5-4dd3-a97f-adbed0674f67 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105% to 112% 103% to 109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e6bf2b3-9339-4104-bda3-ad86a1949703 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
e ratio IU/mL or h † sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:65025e0d-eb54-4c4e-bd14-f294ce038902 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
L 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105–112% 103–109% * Means ± SD at Day 5 and 90% Confidence Interval (CI) of the ratio † Median (range) Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:45a66675-b159-42b8-9f18-ff80f28e1503 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105–112% 103–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20635579-c92d-4f6c-a332-1096d51002f2 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h IU/mL or h Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%–112% 103%–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:adfc2b23-00a5-4f05-a08b-83087e1e4843 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:419a3566-4f67-4c8d-86e5-c00c7ec429e1 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105–112% 103–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7d38c307-767f-4c38-ac0e-b8bb62782602 (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b7197534-1daa-42de-8b83-a727da1195bf (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105%-112% 103%-109% * Means ±SD at Day 5 and 90% Confidence Interval (CI) of the ratio † Median (range) Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a694bbc3-4eb0-4c1e-b4ff-b8abc3e5148e (opens source in a new tab)
Enoxaparin label
Version not recorded · Effective date not recorded
(ss) (h*IU/mL or h* Δ sec) 100 mg/mL 14.26 (±2.93) 1.54 (±0.61) 1321 (±219) 200 mg/mL 15.43 (±2.96) 1.77 (±0.67) 1401 (±227) 90% CI 105–112% 103–109% Distribution The volume of distribution of anti-Factor Xa activity is about 4.3 L.
Projected row 525
- Medicine slug
- entacapone
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
35%
- Numeric value
- 35
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cc1327-5474-4136-970a-ec40c41975b2 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9e94e9f-cd7a-45f5-9aeb-9c28ed804d8c (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d21ce241-b05a-413e-b19a-249ae42012a8 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32d30f97-ae0f-4d02-bdd7-75e0783d66bc (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:863025af-2b71-477d-baa9-3ce7f435e385 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56327e32-3b06-4144-91a0-bb1908842e33 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee02a04a-4b42-4cfa-8d9d-b1459c0ee9fd (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205522fb-bb0e-414e-a413-a08bef727653 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad4b6d79-efd3-4c43-b4dc-5afdacf939a4 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d4ec829-7835-4d59-bc5b-6ce38811fba7 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf133e4-1c17-4358-9a43-144e6bf2564f (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3782792-75c4-418d-be96-9071df475748 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fab63f2-9257-6998-5658-7e98db51b184 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff19d15-c57b-4a40-bba4-1e0a85fd09c5 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
The absolute bioavailability following oral administration is 35%.
Projected row 526
- Medicine slug
- entacapone
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
1.3 hours
- Numeric value
- 1.3
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cc1327-5474-4136-970a-ec40c41975b2 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9e94e9f-cd7a-45f5-9aeb-9c28ed804d8c (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d21ce241-b05a-413e-b19a-249ae42012a8 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32d30f97-ae0f-4d02-bdd7-75e0783d66bc (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:863025af-2b71-477d-baa9-3ce7f435e385 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56327e32-3b06-4144-91a0-bb1908842e33 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee02a04a-4b42-4cfa-8d9d-b1459c0ee9fd (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205522fb-bb0e-414e-a413-a08bef727653 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35%, and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad4b6d79-efd3-4c43-b4dc-5afdacf939a4 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35%, and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d4ec829-7835-4d59-bc5b-6ce38811fba7 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf133e4-1c17-4358-9a43-144e6bf2564f (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3782792-75c4-418d-be96-9071df475748 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fab63f2-9257-6998-5658-7e98db51b184 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff19d15-c57b-4a40-bba4-1e0a85fd09c5 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Effect on the Pharmacokinetics of Levodopa and its Metabolites When 200 mg entacapone is administered together with levodopa and carbidopa, it increases the area under the curve (AUC) of levodopa by approximately 35% and the elimination half-life of levodopa is prolonged from 1.3 hours to 2.4 hours.
Projected row 527
- Medicine slug
- entacapone
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
98%
- Numeric value
- 98
- Unit
- %
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cc1327-5474-4136-970a-ec40c41975b2 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9e94e9f-cd7a-45f5-9aeb-9c28ed804d8c (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d21ce241-b05a-413e-b19a-249ae42012a8 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32d30f97-ae0f-4d02-bdd7-75e0783d66bc (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:863025af-2b71-477d-baa9-3ce7f435e385 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56327e32-3b06-4144-91a0-bb1908842e33 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee02a04a-4b42-4cfa-8d9d-b1459c0ee9fd (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg/mL to 50 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205522fb-bb0e-414e-a413-a08bef727653 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad4b6d79-efd3-4c43-b4dc-5afdacf939a4 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d4ec829-7835-4d59-bc5b-6ce38811fba7 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf133e4-1c17-4358-9a43-144e6bf2564f (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg/mL to 50 mcg/mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3782792-75c4-418d-be96-9071df475748 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fab63f2-9257-6998-5658-7e98db51b184 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff19d15-c57b-4a40-bba4-1e0a85fd09c5 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
Based on in vitro studies, the plasma protein binding of entacapone is 98% over the concentration range of 0.4 mcg per mL to 50 mcg per mL.
Projected row 528
- Medicine slug
- entacapone
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9cc1327-5474-4136-970a-ec40c41975b2 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e9e94e9f-cd7a-45f5-9aeb-9c28ed804d8c (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d21ce241-b05a-413e-b19a-249ae42012a8 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32d30f97-ae0f-4d02-bdd7-75e0783d66bc (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:863025af-2b71-477d-baa9-3ce7f435e385 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56327e32-3b06-4144-91a0-bb1908842e33 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ee02a04a-4b42-4cfa-8d9d-b1459c0ee9fd (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:205522fb-bb0e-414e-a413-a08bef727653 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ad4b6d79-efd3-4c43-b4dc-5afdacf939a4 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d4ec829-7835-4d59-bc5b-6ce38811fba7 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0bf133e4-1c17-4358-9a43-144e6bf2564f (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3782792-75c4-418d-be96-9071df475748 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1fab63f2-9257-6998-5658-7e98db51b184 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bff19d15-c57b-4a40-bba4-1e0a85fd09c5 (opens source in a new tab)
Entacapone label
Version not recorded · Effective date not recorded
In general, the average peak levodopa plasma concentration and the time of its occurrence (T max of 1 hour) are unaffected.
Projected row 529
- Medicine slug
- entecavir
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 12
- Agreement rate
- 1
- Recorded readings
100%
- Numeric value
- 100
- Unit
- %
- Source records
- 12
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 12 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:046e61c9-9298-4b2e-b76e-b26b81fecd20 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1bb6dc-0120-46e2-ad1e-d9afc221fa16 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73dea2a4-a596-477f-b66d-5a80dd019837 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01ec50a1-6c6c-46f0-8c74-73542b0a59c3 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da705339-c349-444f-a058-4f0cef2864bf (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af4f47e2-f556-40f2-a0fd-ff81e9f27429 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d69451df-e204-4a5c-a2bb-9e6d4d519302 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a905283-0057-a7dd-e063-6394a90a1909 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20d62f1a-2e48-69dd-e063-6294a90ace31 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:007a6ad8-4d23-4543-ae48-c651cac7dd7b (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a5bebd-6408-463d-933c-bab8338a677e (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d59e9ea4-09ea-47bd-af2f-39f7a2e2aceb (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
In healthy subjects, the bioavailability of the tablet was 100% relative to the oral solution.
Projected row 530
- Medicine slug
- entecavir
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 16
- Source count
- 16
- Agreement rate
- 1
- Recorded readings
128–149 hours
- Numeric value
- 128
- Unit
- hours
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:046e61c9-9298-4b2e-b76e-b26b81fecd20 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb1bb6dc-0120-46e2-ad1e-d9afc221fa16 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:73dea2a4-a596-477f-b66d-5a80dd019837 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:01ec50a1-6c6c-46f0-8c74-73542b0a59c3 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:da705339-c349-444f-a058-4f0cef2864bf (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a0d2e00d-21f0-4449-93b7-a19fa284d51d (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:af4f47e2-f556-40f2-a0fd-ff81e9f27429 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d69451df-e204-4a5c-a2bb-9e6d4d519302 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a905283-0057-a7dd-e063-6394a90a1909 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:20d62f1a-2e48-69dd-e063-6294a90ace31 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:def332bf-2906-4a6c-b85d-dfb56bb94312 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4fd0e22-ad23-4f51-9b98-95182f63c2eb (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5a1cbf7e-0352-aa3b-080c-222a6423ecd8 (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:007a6ad8-4d23-4543-ae48-c651cac7dd7b (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128 to 149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:92a5bebd-6408-463d-933c-bab8338a677e (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d59e9ea4-09ea-47bd-af2f-39f7a2e2aceb (opens source in a new tab)
Entecavir label
Version not recorded · Effective date not recorded
After reaching peak concentration, entecavir plasma concentrations decreased in a bi-exponential manner with a terminal elimination half-life of approximately 128–149 hours.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=520Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.